In March 2008, the European Commission granted marketing authorization for dabigatran etexilate (Pradaxa; Boehringer Ingelheim), a direct thrombin inhibitor, for the prevention of venous ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback